Who are GP681 Simulant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyvanse, Halflytely, Focalin, Rogaine, DIHYDROCODEINE BITARTRATE, Pyrilamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gp681-simulant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

GP681 Simulant — Competitive Intelligence Brief

GP681 Simulant (GP681 Simulant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Stimulant. Area: Attention Deficit Hyperactivity Disorder (ADHD).

phase 3 Stimulant Attention Deficit Hyperactivity Disorder (ADHD) Small molecule Live · refreshed every 30 min

Target snapshot

GP681 Simulant (GP681 Simulant) — Jiangxi Qingfeng Pharmaceutical Co. Ltd.. GP681 Simulant is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GP681 Simulant TARGET	GP681 Simulant	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	phase 3	Stimulant
Vyvanse	LISDEXAMFETAMINE	Takeda	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2007-01-01
Halflytely	BISACODYL	Braintree	marketed	Stimulant Laxative [EPC]	Kappa-type opioid receptor	2004-01-01
Focalin	DEXMETHYLPHENIDATE	Novartis	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	2001-01-01
Rogaine	minoxidil	Generic (originally Upjohn/Pfizer)	marketed	Vasodilator (potassium channel opener), Hair growth stimulant	ATP-sensitive inward rectifier potassium channel 1, Sulfonylurea receptor 2, Kir6.2	1988-08-18
DIHYDROCODEINE BITARTRATE	DIHYDROCODEINE BITARTRATE		marketed	Central Nervous System Stimulant [EPC]		1983-01-01
Pyrilamine	mepyramine	Impax Labs	marketed	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Stimulant class)

Jiangxi Qingfeng Pharmaceutical Co. Ltd. · 1 drug in this class
UMC Utrecht · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GP681 Simulant — Competitive Intelligence Brief. https://druglandscape.com/ci/gp681-simulant. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab